Gyeonggawon Develops Low-Molecular Candidate Substance Inducing Remodeling of Fat-Accumulating Adipocytes

The Natural Material Team at the Gyeonggi-do Economic Science Promotion Agency is conducting research on new drug substances.

The Gyeonggi-do Economic Science Promotion Agency has developed a low-molecular candidate substance (GBSA-65) that induces remodeling of fat cells, converting fat-storing white fat into fat-burning brown fat.

On the 14th, the agency announced that research results showing metabolic improvement through the anti-obesity candidate substance ‘GBSA-65,’ which induces fat cell remodeling, were published in the June issue of the internationally prestigious journal, European Journal of Pharmaceutical Sciences.

Fat cell remodeling refers to the process of converting white fat into brown fat. White fat functions to store energy, while brown fat burns energy to generate heat, earning it the nickname “fat-burning fat.”

The research team at the agency developed GBSA-65, a low-molecular candidate substance that induces fat cell remodeling, using an obese mouse model fed a high-fat diet. When GBSA-65 was administered to obese mice, their body weight was suppressed by approximately 13.6%. It also showed effects such as improved insulin resistance and reduced cholesterol and triglyceride levels.

In particular, the drug demonstrated excellent characteristics in terms of half-life, bioavailability, solubility, membrane permeability, and metabolic stability.

Kang Seong-cheon, head of the Gyeonggi-do Economic Science Promotion Agency, stated, “Despite the government’s trend of reducing R&D budgets, Gyeonggi-do continues to support R&D to foster the bioindustry and create an ecosystem. We hope that the newly developed GBSA-65 will establish itself as a next-generation innovative anti-obesity drug.”

This content was produced with the assistance of AI translation services.